Cleerly Aims to Reinvent Coronary Artery Diagnostics with AI

“We started Cleerly with the intent to make a comprehensive care pathway for evaluation, education, treatment and tracking for heart disease,” said Dr. Jim Min, the company’s founder and CEO. In this Vanguards of Health Care episode, Min sits down with BI analyst Matt Henriksson to discuss Cleerly and its comprehensive management platform that uses AI algorithms to boost the accuracy of interpreting CT scans, avoid false positives and make the diagnosis stage of treating the disease more efficient for doctors and hospitals. They also cover the need to drive the iterative process of clinical studies, including the TRANSFORM randomized trial for screening asymptomatic individuals with the aim of preventing sudden cardiac death.See omnystudio.com/listener for privacy information.